Literature DB >> 18333849

Malignancies in beta-thalassemia patients: a single-center experience and a concise review of the literature.

L Benetatos1, V Alymara, A Vassou, K L Bourantas.   

Abstract

Thalassemia represents the world's most common monogenic disease, characterized by absence of or decreased globin chain production. The lifespan of thalassemia patients has been extended as a result of current supportive treatment. We report three cases of cancer (non-Hodgkin lymphoma, Hodgkin disease, and seminoma) in thalassemic patients. Factors that may contribute to the pathogenesis of cancer seem to be infections and iron overload through mechanisms of oxidative damage; immunomodulation or coexistence of the two diseases may only be coincidental.

Entities:  

Mesh:

Year:  2008        PMID: 18333849     DOI: 10.1111/j.1751-553X.2007.00929.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  4 in total

1.  A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of β-thalassemia major: A case report.

Authors:  Miguel A Palomo-Colli; Marta Zapata-Tarres; Osvaldo D Castelán-Martínez; Luis E Juárez-Villegas; Lourdes P Córdova-Hurtado
Journal:  Mol Clin Oncol       Date:  2017-12-08

2.  Frequency of thyroid nodules in patients with β-thalassemias in Southern Iran.

Authors:  S Haghpanah; P Pishdad; T Zarei; A Shahsavani; F Amirmoezi; H Ilkhanipoor; H Ilkhanipoor; S Safaei; F Setoodegan; V De Sanctis; M Karimi
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

3.  Hematological malignancies complicating β-thalassemia syndromes: a single center experience.

Authors:  Samin Alavi; Alieh Safari; Elham Sadeghi; Somayeh Amiri
Journal:  Blood Res       Date:  2013-06-25

4.  Thalassemia Intermedia and Acute Lymphoblastic Leukemia: Is it a Coincidental Double Diagnosis?

Authors:  Deniz Tuğcu; Zeynep Karakaş; Müge Gökçe; Leyla Ağaoğlu; Ayşegül Unüvar; Ebru Sarıbeyoğlu; Arzu Akçay; Omer Devecioğlu
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.